Cambridge-based Gen9 Inc. said today it has received a $21 million investment from Agilent Technologies to further invest in product development and expand the "commercial infrastructure" for its synthetic biology business.
As part of the investment, Agilent, which is based in Santa Clara, Calif., has secured an equity stake in the company and will join its board of directors, officials said. Other Gen9 investors include Draper Fisher Jurvetson, The Kraft Group, PBM Capital Group and a number of angel investors, including Scott A. Schoen and Weili Dai.
Gen9, which was founded in 2009 and develops scalable technologies for synthesizing genes, will also incorporate Agilent's Oligonucleotide Library Synthesis technology into its manufacturing process to allow for the large-scale creation of pathway constructs and DNA libraries, the company said.
"Gen9 was founded to significantly increase the world's capacity to cost-effectively generate high-quality DNA content for use in transforming industries ranging from chemical and enzyme production to agriculture, biofuels, pharmaceuticals, and even data storage," said Gen9 President and CEO Kevin Munnelly in a statement. "Agilent's investment is a powerful validation of our proprietary BioFab platform and we look forward to working closely with them to further innovate around our manufacturing capabilities and build Gen9 into the leading high-throughput supplier to the synthetic biology marketplace."
Anda sedang membaca artikel tentang
Gen9 lands $21M investment from Agilent Technologies
Dengan url
http://terdiamtersipu.blogspot.com/2013/04/gen9-lands-21m-investment-from-agilent.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Gen9 lands $21M investment from Agilent Technologies
namun jangan lupa untuk meletakkan link
Gen9 lands $21M investment from Agilent Technologies
sebagai sumbernya
0 komentar:
Posting Komentar